AVIGAN® / REEQONUS
(Favipiravir)

Avigan / REEQONUS (Favipiravir) is a broad spectrum oral antiviral that hits a viral target shared by coronaviruses (SARS-Cov-2, MERS) influenza, and other emerging RNA viruses (Lassa fever).

Originally developed by FUJIFILM Toyama Chemicals Co (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. It is already approved for the treatment of COVID-19 in many countries worldwide.

Favipiravir has been extensively used in many countries since the start of the pandemic, either as an approved drug or on a compassionate use basis.
The effectiveness of Avigan as a treatment for COVID-19 is confirmed by more than 3 million patients who have have received Favipiravir during the pandemic.

Partners

AiPharma is a biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Agility, shareholder of GRA and logistic partner for the distribution of the pharma products

KSE/DFM: AGLTY

FUJI Film Toyama, Originator of Avigan, Fuji cooperates with GRA in manufacturing the drug substance and drug products and in providing the originator technical expertise on Avigan

OTCMKTS: FUJIY

Appili Therapeutics, a key partner in the development and clinical trials of Avigan/REQUONOS in the United States and Canada.

TSE: APLI

Dr. Reddy’s Laboratories, a leading generic pharma company based in India with worldwide production and distribution site, Dr.Reddy is the co-license holder of Avigan working alongside with GRA to manufacture and distribute Avigan

NYSE: RDY

Clinic Design. A leading CRO in Europe, based in Bulgaria, Clinic Design supports the Clinical Trials and the drug development program for GRA

AVIGAN® / REEQONUS

Well understood safety profile, confirmed by the millions of patients that have received Favipiravir during the COVID-19 pandemic

Ideal for mild to moderate symptomatic patients to reduce the number of patients advancing to severe symptoms & requiring hospitalization

A first line of defence strategy for treatment of COVID-19. An oral medication suitable for treatment at home

Shelf stable oral tablet suitable for use in all settings, and compatible with existing stockpiling and distribution channels

Several advantage over generic versions of Favipiravir, including longer shelf life (10 yrs), reduced toxicity & improved bioavailability

Leverages the cornerstone of antiviral therapy, treat early & aggressively before the viral load dramatically increases

Global production capacity already in place. Ready to roll out and distribute

Avigan / Favipiravir is used / approved

The total number of patients treated per country are estimates based on public available information on the sales of Avigan and generic Favipiravir products

MUNA / IoT PCR

Revolutionary blockchain technology trusted by governments and organisations globally to ensure authenticity of COVID-19 test results and vaccine status.

MUNA System Features

Highest level of data security using blockchain

Interoperable with approved PCR machines

Absolute authenticity of every COVID-19 test result

Shared data enables real-time updates across the network for all parties

HIPPA, GDPR & CCPA compliant

Independent compliance audit carried out by EY on every approved provider

Digital vaccine passport

Multi-partner identity ecosystem

Partners

Serving passengers on

MUNA

MUNA is a one-stop solution for COVID-19 testing and vaccination booking, verification and certification, a secure digitized pass ensuring users can resume daily activity with confidence.

Sign up to MUNA today, complete the one time KYC process and benefit from our multi partner ecosystem accepting MUNA as the gold standard in digital identification and certification when it comes to COVID testing and vaccines.

Verifiable digital certificate

Digital vaccine certificate

Book a test – at home or in clinic

Tracker

GRA Team

Mitch
Wilson

Chief Executive Officer

Alex
Gadotti

Chief Financial Officer

Mary
O’Brien

Chief Marketing Officer

John
White

Group Legal Counsel

Dr. Richard
H. Kaszynski

Chief Medical Officer

Mitch
Wilson

Chief Executive Officer

More than 30 years of senior management experience in Logistics, Threat Management and Security.
Mitch is also Executive Director of Strategic Initiatives for the Agility Logistics group.
In a prior role, Mitch has served as Vice President, Middle East & Africa, International Critical Infrastructure Solutions in SOC, a leading company providing mission support to military clients.
Prior to that, Mitch was Vice President in the Threat Management Group, an Agility subsidiary.
Mitch brings experience in preparedness, logistics and strategic management of resources, hence complementing other GRA team members’ strengths in pharmaceuticals with his operational expertise in distribution and logistics.

Alex
Gadotti

Chief Financial Officer

Executive and entrepreneur with more than 30 years experience in Management, M&A, Strategy Consulting and Pharma.
Alex was named the youngest partner at EY at the age of 28. At EY, Alex served as head of the European Strategy Group and co-head of the Technology Innovation Center in Fairfax, VA.
Following EY, Alex became a Partner at Value Partners, a management consulting firm spun out of McKinsey. At Value Partners, Alex led the ‘Value Team’ as co-CEO for the group and CEO for South America, where he managed over 5,000 employees and more than $500M in revenue.
Alex founded MPayMe in Hong Kong, the first technology startup to accept payments on mobile via QR Codes, and which was sold to Powa UK in 2014 in a multi-million-dollar transaction.
At EY and Value Partners, Alex advised numerous leading multinational pharma companies as a Strategy and Business consultant, gaining a profound understanding of the sector.
Alex holds undergraduate degrees in math and statistics, a Ph.D. in Physician Executive MBA sponsored by EY, and a commercial pilot license with more than 8,000 hours of flight time.

Mary
O’Brien

Chief Marketing Officer

Mary joined Global Response Aid bringing 20 years of experience in the healthcare industry. Prior to joining the team, Mary co-founded a digital health business providing on-demand access to physicians and specialists. From 2008 to 2013, Mary co-founded a specialist pharmaceutical development company focused on implantable therapies for opioid addiction disease. Her interest in niche pharmaceutical manufacturing developed from a 2.5-year contract project managing the establishment of Ireland’s first compounding facility, supplying a broad range of extemporaneously compounded medicinal products. From 2000 to 2006 Mary was employed by an fund investing with retail pharmacy in Ireland. Mary holds an MA in HRM, BA HRM and a BSC in Marketing.

John
White

Group Legal Counsel

John has over 25 years' experience in private practice, during this time he spent 16 years as a Partner of international law firm Baker Botts. His experiences include project development and finance, project and asset finance, corporate M&A, joint ventures and international trade

Dr. Richard
H. Kaszynski

Chief Medical Officer

In response to the COVID-19 pandemic, Dr. Kaszynski co-founded the “Global Unified plAtform for the Rapid Development and Investigation of therApeutics for Novel Pandemics (GUARDIAN)” program in collaboration with the Imperial College (London) to optimize clinical studies during outbreaks and pandemics.
Dr. Kaszynski is one of the few physician-scientists with operational and academic experience involving the use of favipiravir and has been instrumental in establishing international COVID-19 clinical trials spanning five continents.
As a Senior Medical Advisor to the Democratic Republic of Congo (DRC), Dr. Kaszynski worked together with the Coordinator General of the Ebola response to identify and implement novel strategies to help combat/contain the Ebola outbreak. It was during the 2019 Ebola outbreak in the North Kivu and Ituri provinces in the DRC where Dr. Kaszynski, together with the DRC Ministry of Foreign Affairs and the Coordinator General for the Ebola outbreak agreed upon proposals for operational deployment of favipiravir in a post-exposure prophylactic capacity.
Dr. Kaszynski holds a Doctor of Medicine from Kobe University (Japan) and was a Fellow at Harvard Medical School, Massachusetts General Hospital in the Department of Anesthesia, Critical Care and Pain Medicine (Boston, MA).

Contact Us

    Global Response Aid

    Visit:

    Emirates Financial Towers,
    Sheikh Zayed Road South Tower,
    Unit: 704C, Dubai, UAE